Mon panier

IgG

IgG Informations sur la molécule

Nom anglaisImmunoglobulin GNombre de médicaments commercialisés1
Nombre de médicaments cliniques8Alias de la cibleImmunoglobulin G
Phase de R&D la plus avancéeApproved
Nom anglaisImmunoglobulin G
Alias de la cibleImmunoglobulin G
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques8
Phase de R&D la plus avancéeApproved

IgG Liste de produits

  • Attribut

    Antibody (6)

  • Bibliothèque de produits

    En ligne (6)

  • Espèces

    Mouse (6)

  • Étiquette

    - (6)

  • Marqueur

    HRP Labeled (1)Acridinium ester Labeled (1)Biotin-labeled (1)PE Labeled (1)Europium chelate Labeled (1)FA Labeled (1)

IgGContexte de la molécule

The Anti-Human IgG-Acridine Ester is an acridinium ester labeled Monoclonal mouse anti-human IgG antibody can be used to capture the human IgG in Chemiluminescence procedures. The antibody reacts with the Fc portion of human IgG heavy chain but not with the Fab portion of human IgG. No antibody was detected against human IgM or IgA, or against non-immunoglobulin serum proteins. The antibody has been tested by ELISA and/or solid-phase adsorbed to ensure minimal cross-reaction with mouse, cynomolgus and bovine serum proteins, but it is not sure if the product cross-react with immunoglobulins from other species. Acridinium ester is one of the most commonly used excited substrates for protein labeling and widely used in automated instruments because of its high sensitivity with detection limits in the attomole range. Acridinium ester can be triggering by chemiluminescent substrate solution and generate intense signal, the result signals (relative light units, RLU) can be measured at 430 nm. The Anti-human IgG-Acridine Ester is easy to capture the human IgG, and the bounded human IgG have no activity lost, this ready to use products could greatly save your protein labeling time and hassle, and help us get the best performance and highly reproducible results.

IgGAlias de la molécule

IgG

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
RicefidaseKJ-103; KJ103Phase 3 ClinicalShanghai Bao Pharmaceuticals Co LtdAnti-Glomerular Basement Membrane Disease; Guillain-Barre Syndrome; Rejection of renal transplantation
Details
AT-02AT-02Phase 2 ClinicalAttralus IncAmyloidosis; Immunoglobulin Light-chain Amyloidosis
Details
JZB-34AAFP; JZB-34Phase 1 ClinicalShanghai Kexin Biotech Co LtdHypersensitivity
Details
Emicizumab biosimilar (Jushi Biopharmaceutical)SYS6053; SYS-6053Phase 1 ClinicalJushi Biopharmaceutical Co LtdHemophilia A; Hemorrhage
Details
S-1117S-1117Phase 1 ClinicalSeismic Therapeutics IncImmune System Diseases
Details
BHV-1300BHV-1300Phase 1 ClinicalBiohaven Pharmaceuticals IncArthritis, Rheumatoid; Graves Disease
Details
HNSA-5487HNSA 5487; HNSA-5487Phase 1 ClinicalHansa Biopharma AbAutoimmune Diseases; Neoplasms
Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
ImlifidaseMac-1ApprovedHansamed IncIdefirixEURejection of renal transplantationHansa Biopharma Ab2020-08-25Guillain-Barre Syndrome; Kidney Diseases; Kidney Failure, Chronic; Purpura, Thrombotic Thrombocytopenic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency, Chronic
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques